Literature DB >> 25702364

Neurocognitive functioning in overweight and obese patients with bipolar disorder: data from the Systematic Treatment Optimization Program for Early Mania (STOP-EM).

Leonardo E Silveira, Jan-Marie Kozicky, Kesavan Muralidharan, Joana Bücker, Ivan J Torres, David J Bond, Flavio Kapczinski, Marcia Kauer-Sant'Anna, Raymond W Lam, Lakshmi N Yatham.   

Abstract

OBJECTIVE: Obesity is frequent in people with bipolar I disorder (BD I) and has a major impact on the course of the illness. Although obesity negatively influences cognitive function in patients with BD, its impact in the early phase of the disorder is unknown. We investigated the impact of overweight and obesity on cognitive functioning in clinically stable patients with BD recently recovered from their first manic episode.
METHOD: Sixty-five patients with BD (25 overweight or obese and 40 normal weight) recently remitted from a first episode of mania and 37 age- and sex-matched healthy control. subjects (9 overweight or obese and 28 normal weight) were included in this analysis from the Systematic Treatment Optimization Program for Early Mania (commonly referred to as STOP-EM). All subjects had their cognitive function assessed using a standard neurocognitive battery. We compared cognitive function between normal weight patients, overweight-obese patients, and normal weight healthy control subjects.
RESULTS: There was a negative affect of BD diagnosis on the domains of attention, verbal memory, nonverbal memory, working memory, and executive function, but we were unable to find an additional effect of weight on cognitive functioning in patients. There was a trend for a negative correlation between body mass index and nonverbal memory in the patient group.
CONCLUSIONS: These data suggest that overweight-obesity does not negatively influence cognitive function early in the course of BD. Given that there is evidence for a negative impact of obesity later in the course of illness, there may be an opportunity to address obesity early in the course of BD.

Entities:  

Mesh:

Year:  2014        PMID: 25702364      PMCID: PMC4304583          DOI: 10.1177/070674371405901205

Source DB:  PubMed          Journal:  Can J Psychiatry        ISSN: 0706-7437            Impact factor:   4.356


  65 in total

Review 1.  Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies.

Authors: 
Journal:  Lancet       Date:  2004-01-10       Impact factor: 79.321

2.  The positive and negative syndrome scale (PANSS) for schizophrenia.

Authors:  S R Kay; A Fiszbein; L A Opler
Journal:  Schizophr Bull       Date:  1987       Impact factor: 9.306

3.  A rating scale for mania: reliability, validity and sensitivity.

Authors:  R C Young; J T Biggs; V E Ziegler; D A Meyer
Journal:  Br J Psychiatry       Date:  1978-11       Impact factor: 9.319

4.  Lower cognitive function in the presence of obesity and hypertension: the Framingham heart study.

Authors:  M F Elias; P K Elias; L M Sullivan; P A Wolf; R B D'Agostino
Journal:  Int J Obes Relat Metab Disord       Date:  2003-02

5.  Metabolic cardiovascular syndrome and risk of dementia in Japanese-American elderly men. The Honolulu-Asia aging study.

Authors:  S Kalmijn; D Foley; L White; C M Burchfiel; J D Curb; H Petrovitch; G W Ross; R J Havlik; L J Launer
Journal:  Arterioscler Thromb Vasc Biol       Date:  2000-10       Impact factor: 8.311

6.  An 18-year follow-up of overweight and risk of Alzheimer disease.

Authors:  Deborah Gustafson; Elisabet Rothenberg; Kaj Blennow; Bertil Steen; Ingmar Skoog
Journal:  Arch Intern Med       Date:  2003-07-14

Review 7.  Bipolar disorder, obesity, and pharmacotherapy-associated weight gain.

Authors:  Paul E Keck; Susan L McElroy
Journal:  J Clin Psychiatry       Date:  2003-12       Impact factor: 4.384

8.  Increased prevalence of type 2 diabetes mellitus among psychiatric inpatients with bipolar I affective and schizoaffective disorders independent of psychotropic drug use.

Authors:  William T Regenold; Ramesh K Thapar; Christopher Marano; Sridevi Gavirneni; Prasad V Kondapavuluru
Journal:  J Affect Disord       Date:  2002-06       Impact factor: 4.839

9.  Prevalence of obesity and weight change during treatment in patients with bipolar I disorder.

Authors:  Andrea Fagiolini; Ellen Frank; Patricia R Houck; Alan G Mallinger; Holly A Swartz; Daniel J Buysse; Hernando Ombao; David J Kupfer
Journal:  J Clin Psychiatry       Date:  2002-06       Impact factor: 4.384

10.  Obesity as a correlate of outcome in patients with bipolar I disorder.

Authors:  Andrea Fagiolini; David J Kupfer; Patricia R Houck; Danielle M Novick; Ellen Frank
Journal:  Am J Psychiatry       Date:  2003-01       Impact factor: 18.112

View more
  4 in total

1.  Differential Impact of Obesity on CD69 Expression in Individuals with Bipolar Disorder and Healthy Controls.

Authors:  Ana S Yamagata; Lucas B Rizzo; Raphael O Cerqueira; Janine Scott; Quirino Cordeiro; Roger S McIntyre; Rodrigo B Mansur; Elisa Brietzke
Journal:  Mol Neuropsychiatry       Date:  2018-02-01

2.  Greater body mass index is associated with reduced frontal cortical volumes among adolescents with bipolar disorder.

Authors:  Alvi H Islam; Arron W S Metcalfe; Bradley J MacIntosh; Daphne J Korczak; Benjamin I Goldstein
Journal:  J Psychiatry Neurosci       Date:  2018-03       Impact factor: 6.186

Review 3.  Call to action regarding the vascular-bipolar link: A report from the Vascular Task Force of the International Society for Bipolar Disorders.

Authors:  Benjamin I Goldstein; Bernhard T Baune; David J Bond; Pao-Huan Chen; Lisa Eyler; Andrea Fagiolini; Fabiano Gomes; Tomas Hajek; Jessica Hatch; Susan L McElroy; Roger S McIntyre; Miguel Prieto; Louisa G Sylvia; Shang-Ying Tsai; Andrew Kcomt; Jess G Fiedorowicz
Journal:  Bipolar Disord       Date:  2020-06-08       Impact factor: 6.744

4.  Impact of metabolic syndrome and clinical features on functioning in patients with bipolar disorder: a cross-sectional study.

Authors:  Hanife Kocakaya; Emrah Songur; Sedat Batmaz; Zekiye Çelikbaş; Önder Küçük
Journal:  Braz J Psychiatry       Date:  2020-03-16       Impact factor: 2.697

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.